Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas

Survival following anthracycline-based chemotherapy remains poor among patients with most T-cell lymphoproliferative disorders. This may be attributed, at least in part, to cell-autonomous mechanisms of chemotherapy resistance observed in these lymphomas, including the loss of important tumor suppre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Murga-Zamalloa, Carlos, Polk, Avery, Hanel, Walter, Chowdhury, Pinki, Brown, Noah, Hristov, Alexandra C., Bailey, Nathanael G., Wang, Tianjiao, Phillips, Tycel, Devata, Sumana, Poonnen, Pradeep, Gomez-Gelvez, Juan, Inamdar, Kedar V., Wilcox, Ryan A.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777707/
https://ncbi.nlm.nih.gov/pubmed/29383095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22967
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares